0.50
-0.17(-25.37%)
Currency In USD
| Previous Close | 0.67 |
| Open | 0.7 |
| Day High | 0.7 |
| Day Low | 0.5 |
| 52-Week High | 4.35 |
| 52-Week Low | 0.25 |
| Volume | 473 |
| Average Volume | 1,650 |
| Market Cap | 1.34M |
| PE | -0.06 |
| EPS | -8.88 |
| Moving Average 50 Days | 0.63 |
| Moving Average 200 Days | 0.73 |
| Change | -0.17 |
If you invested $1000 in Vaccinex, Inc. (VCNX) since IPO date, it would be worth $0.21 as of December 12, 2025 at a share price of $0.5. Whereas If you bought $1000 worth of Vaccinex, Inc. (VCNX) shares 5 years ago, it would be worth $1.2 as of December 12, 2025 at a share price of $0.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
GlobeNewswire Inc.
May 27, 2025 12:45 PM GMT
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechno
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
GlobeNewswire Inc.
Apr 21, 2025 12:45 PM GMT
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appe
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
GlobeNewswire Inc.
Mar 07, 2025 10:15 PM GMT
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis